Neumora Therapeutics Initiates Phase 1 Study on NMRA-898

By Tamara Parker • Monday, October 27 15:31 • Permanent Link

Neumora Therapeutics, Inc. (NASDAQ: NMRA) has recently announced the initiation of a phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898, a structurally distinct M4 muscarinic receptor positive allosteric modulator (PAM). This marks the second M4 PAM in Neumora's M4 franchise, with the first being NMRA-861. Both programs have shown potential best-in-class pharmacology.

The company has confirmed that no convulsions were observed in pre-clinical studies conducted in multiple species, including rabbits. This is a positive indicator of the safety profile of NMRA-898.

Neumora plans to provide a comprehensive M4 franchise update by mid-2026. With both NMRA-898 and NMRA-861 now in the clinic, the company is positioned with exceptional strategic flexibility as it advances two potentially best-in-class M4 PAMs.

The phase 1 SAD/MAD study with NMRA-898 will evaluate the safety, tolerability, and human pharmacokinetic data, confirming the potential for once-daily dosing and central nervous system exposure.

Bill Aurora, Pharm.D., Chief Operating and Development Officer of Neumora, stated, "With both NMRA-898 and NMRA-861 now in the clinic, we are positioned with exceptional strategic flexibility as we advance two potentially best-in-class M4 PAMs. These structurally distinct M4 compounds each demonstrate potential best-in-class pharmacology, giving us the optionality to pursue one or both assets as we advance development."

NMRA-898 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype. Neumora exclusively licensed certain intellectual property rights related to NMRA-898 from the Warren Center for Neuroscience Drug Discovery at Vanderbilt University, including a composition of matter patent extending to 2044.

Schizophrenia, a debilitating neuropsychiatric disorder, impacts approximately 3 million adults in the United States. Neumora's M4 muscarinic receptor-targeting compounds have shown robust antipsychotic activity in multiple, placebo-controlled clinical trials, demonstrating potential as an approach to treating schizophrenia.

Neumora's mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients. Following these announcements, the company's shares moved 13.85%, and are now trading at a price of $2.63. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.